

Development of the National TB and Leprosy Strategy in Nigeria

Dr. Gidado M, MBBS, MPH, MSc.
NTBLTC, Zaria

4th March 2011



Abt Associates Inc.

In collaboration with:

- | Aga Khan Foundation | Bitrán y Asociados
- | BRAC University | Broad Branch Associates
- | Deloitte Consulting, LLP | Forum One Communications
- | RTI International | Training Resources Group
- | Tulane University's School of Public Health

OUTLINE

- HS2020 & Nigeria NTBLCP partnership
- Why new TB and Leprosy Strategy for Nigeria
- Process for the development of the new TB and Leprosy Strategy for Nigeria
- Content of the strategy
- Lessons learnt

Why new TB and Leprosy Strategy fo

- Old Strategy (2006-2010) was expiring
- Need to combine both TB and Leprosy in one Strategy
- Need to align with the new global Stop TB Strategy and Enhanced Global Strategy for Further Reducing the Disease Burden due to Leprosy (2011-2015)
- Need to align with the MDGs
- Based on recommendations of the mid term review of the NSP
- Need to have costed strategy
- Need to have involvement of all current stakeholders

Process for development of the Strategy

- Financial resource mobilization (USAID through HS2020)
- TA resource mobilization (HS20/20, NTBLC, WHO, etc)
- Stakeholder engagement (national and international)
- Logistics for the process (NTBLCP leading the process)
- Series of Stakeholder engagement sessions
- Drafting and redrafting of the Strategy
- Costing of the strategy (HS2020, WHO and ARFH approaches were on the table).
- Currently Strategy at editor's desk before printing

Process

Group work by different stakeholder



Group work



Core writing group





Content of the Strategy (Highlights)

- Reflects both Stop TB Strategy and MDGs
- Has both TB and Leprosy strategic issues addressed
- TB/HIV collaboration
- Public/Private mix
- Community TB care
- Programme Management and Leadership
- MDR TB
- Research
- Laboratory services
- Human resources addressed better

Lessons learnt----1

- Stakeholder engagement important in the process (make use of all available expertise in the country)
- Management of different stakeholder interests necessary in the process



Lessons learnt----2

- TB and Leprosy strategies can and should be handled simultaneously
- Different costing approaches can be applied (HS2020, ARFH and WHO examples)
- National ownership (driving seat), with partners support is the way to go.
- M&E section addressed with its budget line
- HRD plan as a section of the overall strategic plan
- National ownership (driving seat), with partners support is the way to go.
- Simple, clear and well linked, while being comprehensive

Summary of budget

2010 - 2015 TUBERCULOSIS AND LEPROSY STRATEGIC PLAN							
SUMMARY							
THEMATIC AREAS	YEAR 1	YEAR 2	YEAR 3	YEAR 4	YEAR 5	TOTAL	\$ value
	Column1	Column2	Column3	Column4	Column5	Column6	
1 LEPROSY	347,605,900	346,196,235	363,506,047	381,681,349	400,765,417	1,839,754,947	13,141,107
2 Community TB Care (CTBC)	105,032,500	91,402,600	92,316,626	93,239,792	94,172,190	476,163,708	3,401,169
4 Monitoring and Evaluation (M&E)	1,075,067,900	796,247,842	823,526,730	812,252,424	840,079,617	4,347,174,513	31,051,247
5 Human Resources Development (HRD)	2,074,897,838	2,014,609,164	2,062,140,256	2,093,064,669	2,103,589,276	10,348,301,203	73,916,437
6 Advocacy, Communication and Social Mobilization (ACSM)	315,556,000	318,711,560	321,898,676	325,117,662	328,368,839	1,609,652,737	11,497,520
7 Procurement Supply Management (PSM)	1,710,260,323	1,727,362,927	1,744,636,556	1,762,082,922	1,779,703,751	8,724,046,479	62,314,618
8 TB/HIV Collaborative	107,117,100	108,188,271	109,270,154	110,362,855	111,466,484	546,404,864	3,902,892
9 DOTS Expansion	1,403,631,200	1,417,667,512	1,431,844,187	1,446,162,629	1,460,624,255	7,159,929,783	51,142,356
10 Multa Drugs resistance Tuberculosis (MDR)	1,767,327,000	1,785,000,270	1,802,850,273	1,820,878,775	1,839,087,563	9,015,143,881	64,393,885
11 Laboratory	1,476,506,960	1,488,109,417	1,502,990,511	1,518,020,416	1,533,200,620	7,518,827,923	53,705,914
12 Research	242,614,300	245,040,443	247,490,847	249,965,756	252,465,413	1,237,576,760	8,839,834
TOTAL	10,625,617,022	10,731,873,192	247,490,847	249,965,756	252,465,413	22,107,412,231	377,306,977

Thank you

Reports related to this presentation
are available at www.HealthSystems2020.org



Abt Associates Inc.

In collaboration with:

- | Aga Khan Foundation | Bitrán y Asociados
- | BRAC University | Broad Branch Associates
- | Deloitte Consulting, LLP | Forum One Communications
- | RTI International | Training Resources Group
- | Tulane University's School of Public Health